Risk factors
Krystal Biotech (KRYS) risk factors
Item 1A of every Krystal Biotech, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors69 risks6 new8 dropped22 reworded
Krystal Biotech expanded regulatory disclosures, noting the One Big Beautiful Bill Act, and exhausted federal net operating losses in 2025.
Filed Feb 17, 2026 - FY2024 10-K risk factors71 risks
Company growth relies heavily on the commercial success of VYJUVEK and developing new gene therapy product candidates. Operations face stringent regulatory scrutiny, manufacturing challenges, and complex healthcare compliance requirements.
Filed Feb 19, 2025